Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic) (2020 - 2025)

Apellis Pharmaceuticals has reported EPS (Basic) over the past 6 years, most recently at -$0.47 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.47 for Q4 2025, down 62.07% from a year ago — trailing twelve months through Dec 2025 was $0.17 (up 110.69% YoY), and the annual figure for FY2025 was $0.18, up 111.25%.
  • EPS (Basic) for Q4 2025 was -$0.47 at Apellis Pharmaceuticals, down from $1.71 in the prior quarter.
  • Over the last five years, EPS (Basic) for APLS hit a ceiling of $1.71 in Q3 2025 and a floor of -$2.72 in Q2 2021.
  • Median EPS (Basic) over the past 5 years was -$1.1 (2023), compared with a mean of -$1.04.
  • Biggest five-year swings in EPS (Basic): crashed 248.54% in 2021 and later soared 471.74% in 2025.
  • Apellis Pharmaceuticals' EPS (Basic) stood at -$1.53 in 2021, then grew by 1.96% to -$1.5 in 2022, then surged by 52.0% to -$0.72 in 2023, then soared by 59.72% to -$0.29 in 2024, then crashed by 62.07% to -$0.47 in 2025.
  • The last three reported values for EPS (Basic) were -$0.47 (Q4 2025), $1.71 (Q3 2025), and -$0.33 (Q2 2025) per Business Quant data.